A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
- PMID: 26439129
- PMCID: PMC4595076
- DOI: 10.1371/journal.pone.0138348
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Erratum in
-
Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.PLoS One. 2015 Nov 10;10(11):e0142802. doi: 10.1371/journal.pone.0142802. eCollection 2015. PLoS One. 2015. PMID: 26554703 Free PMC article. No abstract available.
Abstract
Background: Replicating smallpox vaccines can cause severe complications in individuals with atopic dermatitis (AD). Prior studies evaluating Modified Vaccinia Ankara virus (MVA), a non-replicating vaccine in humans, showed a favorable safety and immunogenicity profile in healthy volunteers.
Objective: This Phase II study compared the safety and immunogenicity of MVA enrolling groups of 350 subjects with AD (SCORAD ≤ 30) and 282 healthy subjects.
Methods: Subjects were vaccinated twice with MVA, each dose given subcutaneously 4 weeks apart. Adverse events, cardiac parameters, and the development of vaccinia virus humoral immune responses were monitored.
Results: The overall safety of the vaccine was similar in both groups. Adverse events affecting skin were experienced significantly more often in subjects with AD, but the majority of these events were mild to moderate in intensity. Seroconversion rates and geometric mean titers for total and neutralizing vaccinia-specific antibodies in the AD group were non-inferior compared to the healthy subjects.
Limitations: The size of the study population limited the detection of serious adverse events occurring at a frequency less than 1%.
Conclusion: MVA has a favorable safety profile and the ability to elicit vaccinia-specific immune responses in subjects with AD.
Trial registration: ClinicalTrials.gov NCT00316602.
Conflict of interest statement
Figures
![Fig 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4595076/bin/pone.0138348.g001.gif)
![Fig 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4595076/bin/pone.0138348.g002.gif)
![Fig 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4595076/bin/pone.0138348.g003.gif)
Similar articles
-
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.Vaccine. 2014 Sep 29;32(43):5696-702. doi: 10.1016/j.vaccine.2014.08.022. Epub 2014 Aug 20. Vaccine. 2014. PMID: 25149431 Clinical Trial.
-
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.PLoS One. 2018 Apr 13;13(4):e0195897. doi: 10.1371/journal.pone.0195897. eCollection 2018. PLoS One. 2018. PMID: 29652929 Free PMC article. Clinical Trial.
-
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.PLoS One. 2016 Jun 21;11(6):e0157335. doi: 10.1371/journal.pone.0157335. eCollection 2016. PLoS One. 2016. PMID: 27327616 Free PMC article. Clinical Trial.
-
IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.Expert Rev Vaccines. 2009 Jan;8(1):13-24. doi: 10.1586/14760584.8.1.13. Expert Rev Vaccines. 2009. PMID: 19093767 Free PMC article. Review.
-
Clinical development of Modified Vaccinia virus Ankara vaccines.Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21. Vaccine. 2013. PMID: 23523410 Review.
Cited by
-
Biology of Variola Virus.Adv Exp Med Biol. 2024;1451:139-149. doi: 10.1007/978-3-031-57165-7_9. Adv Exp Med Biol. 2024. PMID: 38801576 Review.
-
Predicting vaccine effectiveness for mpox.Nat Commun. 2024 May 8;15(1):3856. doi: 10.1038/s41467-024-48180-w. Nat Commun. 2024. PMID: 38719852 Free PMC article.
-
Monkeypox: Immune response, vaccination and preventive efforts.Narra J. 2022 Dec;2(3):e90. doi: 10.52225/narra.v2i3.90. Epub 2022 Oct 22. Narra J. 2022. PMID: 38449905 Free PMC article. Review.
-
A Review of the Past, Present, and Future of the Monkeypox Virus: Challenges, Opportunities, and Lessons from COVID-19 for Global Health Security.Microorganisms. 2023 Nov 6;11(11):2713. doi: 10.3390/microorganisms11112713. Microorganisms. 2023. PMID: 38004725 Free PMC article. Review.
-
High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope.PLoS Pathog. 2023 Oct 25;19(10):e1011717. doi: 10.1371/journal.ppat.1011717. eCollection 2023 Oct. PLoS Pathog. 2023. PMID: 37878666 Free PMC article.
References
-
- Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975. March;55(3):342–7. - PubMed
-
- Lane JM, Frederick L, Ruben FL, Neff JM, Millar JD . Complications of smallpox vaccination, 1968. N Engl J Med 1969. November 27;281(22):1201–8. - PubMed
-
- Lane JM, Frederick L, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: Results of ten statewide surveys. J Infect Dis 1970. October;122(4):303–9. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical